Questions
Q1: Natalizumab PML was a known risk once it went to market in 2004/5, and from my reading, it was a shock. Why did nothing come out during the trials? Surely there would’ve been a PML scare during phases 2-3? I can’t see any literature on this, but it seems that this shocked the community when it came to market, so I’m curious why nothing popped up during the trials, and if it did, was it hidden, or they didn’t know?
Q2: Besides having MS, I am regularly (weakly) positive for EBV IgM. What does this mean?
Q3: I was moved from Gilenya to generic fingolimod tablets last year. Over the past few months, I have noticed a worsening of side effects and wonder if it could be a consequence of the new generic version of the drug.
The main worsened side effects noticed:
Recurrence of warts on fingers and thumb
Sickness / fuzzy / dizziness sensations
Occasional blood when going to the toilet
Vivid and weird dreams
Do you think these are related to generic fingolimod?
NOTE: General substack newsletters and microsite are free; only Q&A sessions are restricted to paying subscribers. I can't run and maintain the MS-Selfie microsite, hence the need to pay people to help me do the work. If people want to ask medical questions unrelated to the Newsletters or Podcasts, they either need to become paying subscribers or email (ms-selfie@giovannoni.net) to request a complimentary subscription.
Answers
Listen to this episode with a 7-day free trial
Subscribe to MS-Selfie to listen to this post and get 7 days of free access to the full post archives.
